Literature DB >> 29893751

Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.

Hyung Rae Kim1, Minjung Seo2, Yang Won Nah3, Hyung Woo Park3, Seol Hoon Park2.   

Abstract

PURPOSE: To evaluate the diagnostic accuracy of fluorine-18-fluorodeoxyglucose PET/computed tomography (F-FDG PET/CT) for lymph node (LN) metastasis and the prognostic significance of F-FDG PET/CT LN parameters in patients with resectable pancreatic cancer. PATIENTS AND METHODS: Patients with resectable pancreatic cancer who underwent staging F-FDG PET/CT between May 2007 and September 2016 were retrospectively enrolled and analyzed through medical record and image re-evaluation. The diagnostic accuracy of F-FDG PET/CT in predicting LN metastasis was evaluated and compared with that of contrast-enhanced abdominal computed tomography (CECT). Prognostic variables, including LN parameters assessed by F-FDG PET/CT [standardized uptake value (SUV)LN and LN/tumor SUV ratio], that affect disease-free survival (DFS) and overall survival (OS) were evaluated by regression analysis.
RESULTS: When predicting LN metastasis, F-FDG PET/CT showed greater sensitivity, positive predictive value, negative predictive value, and accuracy than CECT. Among prognostic factors affecting DFS, PET-positive LN (P=0.008), and LN/tumor SUV ratio (P=0.003) were found to be significant by regression analysis. Among the variables affecting OS, lymphovascular invasion (P=0.018) and the LN/tumor SUV ratio (P=0.046) were found to be significant.
CONCLUSION: F-FDG PET/CT showed higher diagnostic accuracy in predicting LN metastasis than CECT in patients with resectable pancreatic cancer. Only the LN/tumor SUV ratio of F-FDG PET/CT was an independent prognostic variable in both DFS and OS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29893751     DOI: 10.1097/MNM.0000000000000855

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  Prognostic Significance of Microvascular Invasion in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Huangbao Li; Weiwei Pan; Liu Xu; Dong Yin; Shuqun Cheng; Fengqing Zhao
Journal:  Med Sci Monit       Date:  2021-08-16

Review 2.  [Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma].

Authors:  Shin Hye Hwang; Mi-Suk Park
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-03-31

3.  Accuracy of various criteria for lymph node staging in ductal adenocarcinoma of the pancreatic head by computed tomography and magnetic resonance imaging.

Authors:  Florian N Loch; Patrick Asbach; Matthias Haas; Hendrik Seeliger; Katharina Beyer; Christian Schineis; Claudius E Degro; Georgios A Margonis; Martin E Kreis; Carsten Kamphues
Journal:  World J Surg Oncol       Date:  2020-08-18       Impact factor: 2.754

4.  Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy.

Authors:  Chia-Hsin Lin; Tsung-Min Hung; Yu-Chuan Chang; Chia-Hsun Hsieh; Ming-Chieh Shih; Shih-Ming Huang; Chan-Keng Yang; Ching-Fu Chang; Sheng-Chieh Chan; Wing-Keen Yap
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

Review 5.  The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review.

Authors:  Yongzhu Pu; Chun Wang; Sheng Zhao; Ran Xie; Lei Zhao; Kun Li; Conghui Yang; Rui Zhang; Yadong Tian; Lixian Tan; Jindan Li; Shujuan Li; Long Chen; Hua Sun
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.